查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012938

脑肿瘤诊断与治疗市场：依治疗方法、诊断方法、肿瘤类型及最终用户划分－2026-2032年全球市场预测

Brain Tumor Diagnosis & Treatment Market by Treatment Type, Diagnosis Type, Tumor Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，脑肿瘤诊断和治疗市场价值将达到 19.3 亿美元，到 2026 年将成长到 20.6 亿美元，到 2032 年将达到 31.1 亿美元，复合年增长率为 7.06%。

主要市场统计数据
基准年 2025 19.3亿美元
预计年份：2026年 20.6亿美元
预测年份 2032 31.1亿美元
复合年增长率 (%) 7.06%

本书清晰而有力地介绍了正在重塑全球脑肿瘤诊断和治疗路径的临床、技术和营运趋势。

脑肿瘤的诊断和治疗处于快速科学创新和复杂临床决策的交汇点，对临床医生、研究人员和医疗系统领导者提出了严谨的应对要求。分子生物学、影像技术和治疗方法的进步提高了诊断的准确性和治疗选择，但也为患者选择、临床工作流程、保险报销和监管协调等领域带来了新的复杂性。因此，相关人员必须权衡新治疗方法的潜力与实际限制因素，例如设备获取、跨学科合作以及长期治疗效果的评估。

详细检视诊断、治疗和数位技术的融合，重新定义脑肿瘤治疗和临床决策中的精准医疗之路。

脑肿瘤生态系统正经历着一场变革性的转变，这得益于诊断、治疗和数据驱动型医疗服务等领域的进步。影像学已从解剖学描述发展到功能和分子表征，从而能够更早检测治疗反应和復发，并制定更精细的手术方案。同时，分子诊断技术的进步，包括基因表现分析、次世代定序和基于PCR的检测方法，正在重新定义肿瘤的分类和预后，为治疗方法的选择提供日益关键的资讯。

对近期贸易政策调整和关税趋势如何影响脑肿瘤治疗的供应链、筹资策略和临床实施进行严谨的分析。

贸易和关税政策的变化可能会对临床供应链、科学研究采购和医疗设备的供应产生连锁反应，进而影响脑瘤治疗的实施。进口关税和监管要求的变化可能会增加采购先进影像设备、立体定位手术器械和专用一次性用品的成本和复杂性，同时也会影响分子诊断和次世代定序流程中所用试剂的供应和价格。这些下游压力可能会加重诊断检查室和影像中心的运作负担，减缓设备升级速度，并限制新诊断方法在常规临床实践中的应用。

透过对治疗方法、诊断流程、最终用户和肿瘤亚型进行细緻的细分，主导全面的整合，从而指导策略优先排序。

以细分观点为出发点，明确了在每个诊断和治疗路径中应将投资和运营重点放在哪里，从而最有效地加速以患者为中心的治疗效果。根据治疗类型，整体情况包括化疗、免疫疗法、放射线治疗、手术和标靶治疗。在这些类别中，化疗方案包括联合治疗、亚硝基脲类药物和Temozolomide；免疫疗法包括CAR-T细胞疗法、查核点抑制剂和疫苗；放射线治疗包括近距离放射、体外放射治疗和立体定位放射放射线手术。标靶治疗方案包括Bevacizumab、mTOR抑制剂和蛋白酪氨酸激酶抑制剂，每种药物的作用机制各不相同，因此需要量身定制的诊断策略和疗效评估方法。

对影响全球医疗保健系统准入和部署的区域部署模式、基础设施趋势和政策背景进行详细评估。

区域趋势显着影响着整个医疗保健系统中诊断创新和治疗方法的引入、推广和报销方式。在美洲，临床生态系统大规模综合大学医院到社区医院的各种类型，为技术应用、强化专科医疗服务和多中心合作研究创造了多元化的途径。该地区的筹资策略和报销模式决定了先进影像、立体定位治疗平台和分子检测融入常规实践的速度。在欧洲、中东和非洲，情况则呈现异质性，法律规范、医疗保健系统资金筹措和基础设施的差异导致了不同的技术应用曲线。虽然功能强大的医疗中心遍布该地区，但在其他地区，获得复杂诊断和专科手术的机会仍然有限，导致这些地区依赖转诊网路和区域卓越医疗中心。

对竞争动态、伙伴关係策略和创新重点领域进行深入分析。

脑肿瘤诊断和治疗生态系统的竞争动态呈现出多元化的态势，既有成熟的生物医药公司，也有新兴的生物技术创新者、专业医疗设备製造商和诊断检测实验室。大型医疗设备和製药公司持续利用其规模、监管经验和分销网络，支援影像平台、立体定位放射治疗系统和已通过核准疗法的广泛临床应用。同时，小规模的专业公司和大学衍生企业正在精准放射治疗计划、分子检测开发和新型免疫疗法等细分领域推动创新，并经常与大型机构合作，推进后期研发和商业化进程。

一系列可操作且有优先顺序的策略行动，领导者可以采取这些行动来确保诊断准确性和治疗创新带来公平的临床结果。

产业领导者必须采取前瞻性策略，将技术潜力转化为切实的临床价值和公平的医疗服务取得途径。首先，投资整合诊断到治疗的一体化流程，将分子谱分析、先进影像技术和多学科临床决策无缝整合到一个统一的工作流程中。优先考虑互通性和数据标准将简化病例审查流程，并加快治疗方法的选择。其次，透过多元化供应商关係，增强供应链的韧性，确保专用耗材、试剂和资本设备的供应，并制定紧急时应对计画，以应对因政策变化或物流限製而导致的采购中断。

透明且以临床证据为基础的调查方法，结合了与专家的初步访谈、系统性的文献整合和多方面的检验，作为分析的基础。

本分析采用的研究方法结合了多种定性和定量方法，以确保获得全面且检验的见解。主要调查包括对临床专业人员、实验室管理人员、医院采购人员和行业高管进行结构化访谈，以收集关于诊断流程、治疗决策和营运限制的第一手观点。次要调查则係统地回顾了同侪审查文献、临床指南更新、监管公告和公共卫生政策文件，以了解临床实践和技术进步的背景。

简洁而明确的结论，将实现诊断技术进步、治疗方法多样化和改善患者预后所需的系统性要求联繫起来。

本执行摘要全面概述了诊断创新、治疗方法多样化和系统性因素如何影响现代脑肿瘤治疗。分子诊断和影像诊断的进步提高了诊断准确性，并实现了治疗分层。同时，标靶治疗、免疫疗法和放射疗法的改进也拓展了治疗选择。儘管这些进步为改善治疗效果创造了机会，但协调投资于基础设施、人力资源发展和实证医学研究对于确保安全有效地实施至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：脑肿瘤诊断与治疗市场（依治疗方法划分）

  • 化疗
    • 联合治疗
    • 亚硝基脲类药物
  • 免疫疗法
    • CAR-T细胞疗法
    • 查核点抑制剂
    • 疫苗
  • 放射线治疗
  • 外科手术
  • 分子标靶治疗

第九章：脑肿瘤诊断与治疗市场（依诊断方法划分）

  • 切片检查
    • 开放式切片检查
    • 立体定位切片检查
  • 诊断影像
    • 电脑断层扫描
    • 磁振造影
    • 正子断层扫描
    • 超音波
  • 分子诊断
    • 基因表现分析
    • 次世代定序
    • 基于PCR的检测

第十章：依肿瘤类型分類的脑肿瘤诊断与治疗市场

  • 胶质瘤
    • 星状细胞瘤
    • 胶质母细胞瘤
    • 少突胶质细胞瘤
  • 髓母细胞瘤
  • 脑膜瘤
  • 脑下垂体瘤
    • 颅咽瘤
    • 脑下垂体腺瘤

第十一章：脑肿瘤诊断与治疗市场：依最终使用者划分

  • 诊断中心
  • 医院
  • 研究机构
  • 专科诊所

第十二章：脑肿瘤诊断与治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：脑肿瘤诊断与治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 脑肿瘤诊断与治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国脑肿瘤诊断与治疗市场。

第十六章：中国脑肿瘤诊断与治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accuray Incorporated
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Canon Medical Systems Corporation
  • Eisai Co., Ltd.
  • Elekta AB
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare LLC
  • Hitachi, Ltd.
  • Koninklijke Philips NV
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure Limited
  • Pfizer Inc.
  • Roche Holding AG
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Varian Medical Systems, Inc.
Product Code: MRR-437D459585B5

The Brain Tumor Diagnosis & Treatment Market was valued at USD 1.93 billion in 2025 and is projected to grow to USD 2.06 billion in 2026, with a CAGR of 7.06%, reaching USD 3.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.93 billion
Estimated Year [2026] USD 2.06 billion
Forecast Year [2032] USD 3.11 billion
CAGR (%) 7.06%

A clear and compelling introduction to the evolving clinical, technological, and operational landscape reshaping brain tumor diagnosis and treatment pathways globally

Brain tumor diagnosis and treatment sit at the intersection of rapid scientific innovation and complex clinical decision-making, demanding rigorous navigation by clinicians, researchers, and health system leaders. Advances in molecular biology, imaging technology, and therapeutic modalities have expanded diagnostic precision and therapeutic options, yet they have also introduced new layers of complexity around patient selection, procedural workflows, reimbursement, and regulatory alignment. Consequently, stakeholders must reconcile the promise of novel interventions with real-world constraints such as equipment access, interdisciplinary coordination, and long-term outcome measurement.

Over the past decade, the clinical narrative has shifted from one-size-fits-all strategies toward more personalized approaches that integrate molecular insights with advanced imaging and targeted therapies. As a result, frontline practice increasingly relies on integrated diagnostic pathways that combine biopsy techniques, imaging modalities, and molecular assays to produce a nuanced understanding of tumor biology. This evolution has immediate implications for clinical workflows, laboratory operations, and cross-disciplinary training, and it creates opportunities for vendors and health systems to reimagine service delivery models.

Looking ahead, the ability to translate diagnostic precision into durable therapeutic benefit will hinge on coordinated improvements across diagnostics, surgery, systemic therapies, and supportive care. Health systems that proactively invest in cross-functional capabilities-ranging from hybrid operating suites and stereotactic platforms to molecular pathology and data integration-will be better positioned to operationalize emerging evidence and improve patient outcomes. This introduction frames the subsequent sections, which explore transformational shifts, tariff-related impacts, segmentation insights, regional dynamics, competitive considerations, and actionable recommendations for leaders navigating this evolving landscape.

An in-depth examination of converging diagnostic, therapeutic, and digital innovations that are redefining precision pathways for brain tumor care and clinical decision-making

The brain tumor ecosystem is undergoing transformative shifts driven by converging advances in diagnostics, therapeutics, and data-driven care delivery. Imaging has moved beyond anatomical depiction to functional and molecular characterization, enabling earlier detection of treatment response and recurrence and permitting more nuanced surgical planning. Parallel advances in molecular diagnostics, including gene expression profiling, next generation sequencing, and PCR-based assays, have redefined tumor classification and prognostication, and they increasingly inform therapeutic selection.

On the therapeutic front, targeted agents and immunotherapies are changing the treatment algorithm. Targeted Therapy options such as bevacizumab, mTOR inhibitors, and tyrosine kinase inhibitors provide mechanistic precision for select tumor subtypes, while immunotherapy approaches including CAR T-cell therapy, checkpoint inhibitors, and cancer vaccines are extending lines of inquiry into durable anti-tumor immunity. Radiotherapy innovation, spanning external beam modalities, stereotactic radiosurgery, and brachytherapy, is enhancing focal control with reduced collateral toxicity. Surgical technology has likewise advanced, with image-guided resection and minimally invasive stereotactic approaches improving the balance between maximal resection and functional preservation.

Digital transformation is amplifying these clinical innovations. Artificial intelligence and machine learning augment imaging interpretation, automate segmentation, and support prognostic modeling, thereby shortening diagnostic timelines and enabling more personalized surveillance strategies. Interoperability of clinical and genomic data supports multidisciplinary tumor boards and accelerates translational research. Taken together, these shifts are creating a landscape in which precision diagnostics and multimodal treatment converge to offer individualized pathways, while simultaneously raising pressing questions about equitable access, reimbursement policy, and the workforce competencies required to realize these benefits at scale.

A rigorous analysis of how recent trade policy adjustments and tariff dynamics are influencing supply chains, procurement strategies, and clinical adoption in brain tumor care

Policy shifts in trade and tariffs can produce ripple effects across clinical supply chains, research procurement, and device availability that materially influence the delivery of brain tumor care. Changes to import duties and regulatory requirements raise the cost and complexity of sourcing advanced imaging hardware, stereotactic equipment, and specialized disposables, while also affecting the availability and pricing of reagents used in molecular diagnostics and next generation sequencing workflows. These downstream pressures can increase operational burden for diagnostic laboratories and imaging centers, delay capital upgrades, and constrain the pace at which new diagnostic modalities are adopted in routine clinical practice.

Beyond direct procurement impacts, tariff-driven shifts can reshape partnerships between domestic and international suppliers, prompting manufacturers to reevaluate production footprints and supply chain redundancy. In response, providers and research institutions may prioritize strategic procurement, develop longer inventory lead times, and diversify vendor relationships to mitigate supply risk. Importantly, tariff-induced cost pressures can also influence pricing negotiations with payers, slow adoption of capital-intensive therapeutic platforms, and prompt system-level decisions around where specialized services are centralized to achieve economies of scale.

For research networks and clinical trials, changes to cross-border movement of biological materials, instrumentation, and diagnostic kits can introduce logistical hurdles that affect trial initiation and sample processing timelines. Consequently, research sponsors and clinical investigators must anticipate and incorporate trade-related contingencies into study design and budgeting. In the aggregate, tariff dynamics act as a non-clinical determinant of access and innovation, underscoring the need for proactive supply chain strategies, policy engagement, and adaptive procurement models to preserve the momentum of improvements in brain tumor diagnosis and treatment.

A comprehensive segmentation-driven synthesis connecting treatment modalities, diagnostic workflows, end users, and tumor subtype nuances to guide strategic prioritization

A segmentation-aware perspective illuminates where investment and operational focus will most effectively accelerate patient-centered outcomes across diagnostic and therapeutic pathways. Based on Treatment Type, the clinical landscape encompasses Chemotherapy, Immunotherapy, Radiotherapy, Surgery, and Targeted Therapy; within these categories, Chemotherapy pathways include combination therapies, nitrosoureas, and temozolomide, while Immunotherapy encompasses CAR T-cell therapy, checkpoint inhibitors, and vaccines, and Radiotherapy comprises brachytherapy, external beam radiotherapy, and stereotactic radiosurgery. Targeted Therapy options span bevacizumab, mTOR inhibitors, and tyrosine kinase inhibitors, each offering distinct mechanisms that require aligned diagnostic strategies and outcome measurement.

Diagnostic segmentation further clarifies clinical workflows and laboratory needs. Based on Diagnosis Type, the diagnostic continuum includes biopsy, imaging, and molecular diagnostics; biopsy procedures range from open biopsy to stereotactic biopsy, imaging modalities include computed tomography, magnetic resonance imaging, positron emission tomography, and ultrasound, and molecular diagnostics incorporate gene expression profiling, next generation sequencing, and PCR-based assays to provide molecular context for therapeutic choice and prognostication. These diagnostic modalities interact closely with treatment selection and surveillance paradigms and inform the design of multidisciplinary care pathways.

End user segmentation highlights where services are delivered and where capacity constraints may emerge. Based on End User, care is provided across diagnostic centers, hospitals, research institutes, and specialty clinics, each with distinct infrastructure, staffing models, and reimbursement interfaces. Tumor type segmentation brings clinical heterogeneity into focus. Based on Tumor Type, the principal categories include glioma, medulloblastoma, meningioma, and pituitary tumor; glioma includes astrocytoma, glioblastoma, and oligodendroglioma, while pituitary tumor distinctions include craniopharyngioma and pituitary adenoma. Aligning therapeutic modalities and diagnostic intensity with tumor subtype is essential for optimizing outcomes and resource allocation, and it emphasizes the need for integrated care pathways that span diagnosis through long-term surveillance.

A nuanced assessment of regional adoption patterns, infrastructure dynamics, and policy contexts shaping access and implementation across global health systems

Regional dynamics exert a profound influence on how diagnostic innovations and therapeutic modalities are adopted, scaled, and reimbursed across health systems. In the Americas, clinical ecosystems vary from large integrated academic medical centers to community hospitals, producing diverse pathways for technology adoption, centralized specialty services, and multisite research collaboration; procurement strategies and reimbursement models in this region shape the pace at which advanced imaging, stereotactic platforms, and molecular testing are integrated into standard practice. Europe, Middle East & Africa presents a heterogeneous picture in which regulatory frameworks, health system financing, and infrastructure disparities create differentiated adoption curves; pockets of high-capacity centers coexist with regions where access to complex diagnostics and specialty surgery remains limited, prompting a reliance on referral networks and regional centers of excellence.

Asia-Pacific demonstrates rapid capacity expansion in both clinical infrastructure and domestic manufacturing of diagnostic reagents and medical devices, accompanied by growing participation in international clinical research and cross-border collaboration. The convergence of public investment in tertiary healthcare and increased private sector involvement in many Asia-Pacific markets accelerates the diffusion of technology, while also creating varied payer landscapes that affect affordability and access. Across all regions, interoperability of clinical and genomic data, workforce training, and telemedicine-enhanced networks act as enablers for expanding access to specialist expertise. Understanding regional nuances is critical for tailoring implementation strategies, aligning commercial engagement, and structuring collaborative research that accounts for local regulatory, economic, and clinical realities.

An incisive review of competitive dynamics, partnership strategies, and innovation focus areas that determine which companies will drive clinical adoption and service evolution

Competitive dynamics in the brain tumor diagnosis and treatment ecosystem reflect a blend of established biomedical firms, emerging biotechnology innovators, specialized device manufacturers, and diagnostic laboratories. Large medical device and pharmaceutical companies continue to leverage scale, regulatory experience, and distribution networks to support wide clinical deployment of imaging platforms, stereotactic systems, and approved therapeutics. At the same time, smaller specialized firms and academic spin-outs drive innovation in niche areas such as precision radiotherapy planning, molecular assay development, and novel immunotherapeutic constructs, often partnering with larger organizations to progress late-stage development and commercialization.

Strategic collaborations between diagnostics providers and therapeutic developers are becoming increasingly important as treatment decisions rely on integrated biomarker and imaging information. Partnerships that bridge laboratory-developed tests, next generation sequencing, and clinical trial networks facilitate patient stratification and accelerate translational pipelines. Intellectual property strategy, regulatory pathway navigation, and real-world evidence generation are key differentiators for companies that seek durable clinical adoption. Moreover, contract research organizations, specialty service providers, and regional distributors play a pivotal role in enabling clinical trial logistics and localized deployment of complex technologies.

For stakeholders evaluating competitor behavior, attention should focus on areas of active investment such as molecular diagnostics platforms, AI-enabled imaging solutions, stereotactic radiosurgery systems, and cell therapy manufacturing capacity. Companies that combine robust clinical evidence generation with clear reimbursement strategies and scalable service models are best positioned to transform innovations into widespread clinical utility. Ultimately, success hinges on aligning commercial strategy with clinical workflows, payer requirements, and the operational realities of centers delivering neuro-oncology care.

A set of practical and prioritized strategic actions that leaders can implement to ensure diagnostic precision and therapeutic innovation translate into equitable clinical impact

Industry leaders must adopt proactive strategies to translate technological potential into consistent clinical value and equitable access. First, invest in integrated diagnostic-to-therapy pathways that bring molecular profiling, advanced imaging, and multidisciplinary clinical decision-making into seamless workflows; prioritizing interoperability and data standards will streamline case review and accelerate therapy selection. Second, strengthen supply chain resilience by diversifying vendor relationships for specialized consumables, reagents, and capital equipment, and by developing contingency plans that address procurement disruptions caused by policy shifts or logistical constraints.

Third, forge collaborative partnerships across academic centers, community providers, and industry to broaden patient access to specialized diagnostics and novel therapies, while also enabling larger, more representative clinical studies. Fourth, align evidence generation with payer expectations by designing clinical and real-world studies that demonstrate comparative effectiveness, patient-centered outcomes, and cost implications relevant to reimbursement decisions. Fifth, invest in workforce development and cross-disciplinary training to ensure clinicians, pathologists, radiologists, and laboratory staff can operationalize complex diagnostic algorithms and deliver multimodal treatments safely and effectively.

Finally, adopt a patient-centric commercialization strategy that considers equity and affordability, including tiered delivery models, telemedicine-enabled networks, and regional centers of excellence that concentrate high-complexity care. By implementing these actions, leaders can convert scientific advances into scalable clinical benefits while managing operational risk and strengthening stakeholder alignment across health systems.

A transparent and clinically grounded methodology combining primary expert interviews, systematic literature synthesis, and multi-source validation to underpin the analysis

The research approach underpinning this analysis combined multifaceted qualitative and quantitative methods to ensure comprehensive and validated findings. Primary research comprised structured interviews with clinical specialists, laboratory directors, hospital procurement leaders, and industry executives to capture firsthand perspectives on diagnostic workflows, therapeutic decision-making, and operational constraints. Secondary research involved systematic review of peer-reviewed literature, clinical guideline updates, regulatory communications, and public health policy documents to contextualize clinical practice and technology trajectories.

Data synthesis employed triangulation techniques to reconcile insights from primary interviews with published evidence and industry disclosures. Validation rounds with subject matter experts ensured that interpretations of technological capability, regulatory pathways, and operational feasibility reflected current practice patterns. Ethical considerations guided the research, including protection of confidential information shared during interviews and de-identification of sensitive operational details. Limitations of the methodology included variability in regional data granularity and evolving evidence bases for emerging therapies; where appropriate, findings emphasize directional insights and implementation considerations rather than definitive long-term projections.

Overall, the methodology prioritized transparency, cross-validation, and clinical relevance to produce an analysis that supports operational decision-making, strategic planning, and further research collaboration within the brain tumor diagnosis and treatment domain.

A concise and decisive conclusion tying together diagnostic advances, therapeutic diversification, and systemic imperatives required to realize improved patient outcomes

This executive summary synthesizes how diagnostic innovation, therapeutic diversification, and systemic factors jointly shape contemporary brain tumor care. Advances in molecular diagnostics and imaging have enhanced diagnostic precision and informed treatment stratification, while targeted therapies, immunotherapies, and radiotherapy refinements are expanding therapeutic options. These developments create opportunities for improved outcomes but also necessitate coordinated investments in infrastructure, workforce training, and evidence generation to ensure safe and effective adoption.

External forces such as trade policy dynamics and regional infrastructure disparities influence the speed and equity of implementation, affecting procurement, research logistics, and access to advanced care. Competitive dynamics reveal that successful entities will be those that integrate diagnostic and therapeutic value propositions, demonstrate clinical and economic value, and build scalable service delivery models. Actionable recommendations center on creating integrated pathways, strengthening supply chain resilience, fostering collaborative networks, aligning evidence generation with payer needs, and committing to workforce and access initiatives.

In closing, realizing the promise of improved brain tumor care will require coordinated action across clinicians, health systems, industry, and policymakers. Stakeholders who proactively align technological capability with operational readiness and equitable delivery models will be best positioned to convert innovation into meaningful patient benefit and sustainable system impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Tumor Diagnosis & Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Combination Therapies
    • 8.1.2. Nitrosoureas
  • 8.2. Immunotherapy
    • 8.2.1. Car T-Cell Therapy
    • 8.2.2. Checkpoint Inhibitors
    • 8.2.3. Vaccines
  • 8.3. Radiotherapy
  • 8.4. Surgery
  • 8.5. Targeted Therapy

9. Brain Tumor Diagnosis & Treatment Market, by Diagnosis Type

  • 9.1. Biopsy
    • 9.1.1. Open Biopsy
    • 9.1.2. Stereotactic Biopsy
  • 9.2. Imaging
    • 9.2.1. Computed Tomography
    • 9.2.2. Magnetic Resonance Imaging
    • 9.2.3. Positron Emission Tomography
    • 9.2.4. Ultrasound
  • 9.3. Molecular Diagnostics
    • 9.3.1. Gene Expression Profiling
    • 9.3.2. Next Generation Sequencing
    • 9.3.3. Pcr-Based Assays

10. Brain Tumor Diagnosis & Treatment Market, by Tumor Type

  • 10.1. Glioma
    • 10.1.1. Astrocytoma
    • 10.1.2. Glioblastoma
    • 10.1.3. Oligodendroglioma
  • 10.2. Medulloblastoma
  • 10.3. Meningioma
  • 10.4. Pituitary Tumor
    • 10.4.1. Craniopharyngioma
    • 10.4.2. Pituitary Adenoma

11. Brain Tumor Diagnosis & Treatment Market, by End User

  • 11.1. Diagnostic Centers
  • 11.2. Hospitals
  • 11.3. Research Institutes
  • 11.4. Specialty Clinics

12. Brain Tumor Diagnosis & Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Brain Tumor Diagnosis & Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Brain Tumor Diagnosis & Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Brain Tumor Diagnosis & Treatment Market

16. China Brain Tumor Diagnosis & Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Accuray Incorporated
  • 17.6. AstraZeneca PLC
  • 17.7. Bayer AG
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Canon Medical Systems Corporation
  • 17.10. Eisai Co., Ltd.
  • 17.11. Elekta AB
  • 17.12. F. Hoffmann-La Roche Ltd.
  • 17.13. GE Healthcare LLC
  • 17.14. Hitachi, Ltd.
  • 17.15. Koninklijke Philips N.V.
  • 17.16. Merck & Co., Inc.
  • 17.17. Novartis AG
  • 17.18. Novocure Limited
  • 17.19. Pfizer Inc.
  • 17.20. Roche Holding AG
  • 17.21. Siemens Healthineers AG
  • 17.22. Thermo Fisher Scientific Inc.
  • 17.23. Varian Medical Systems, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY ADENOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY ADENOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY ADENOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 234. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 235. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 238. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 239. GCC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 270. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 271. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 272. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 274. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 275. G7 BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 283. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 284. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2032 (USD MILLION)
  • TABLE 286. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2032 (USD MILLION)
  • TABLE 287. NATO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES BRAIN TUMOR DIA